Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Suprit Parida, Kathleen M. Carroll, Ismene L. Petrakis & Mehmet Sofuoglu. (2019) Buprenorphine treatment for opioid use disorder: recent progress. Expert Review of Clinical Pharmacology 12:8, pages 791-803.
Read now
Read now
Yatan Pal Singh Balhara, Shalini Singh & Siddharth Sarkar. (2019) Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction. Substance Use & Misuse 54:2, pages 307-314.
Read now
Read now
Lynn Webster, Peter Hjelmström, Michael Sumner & Erik W. Gunderson. (2016) Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Journal of Addictive Diseases 35:4, pages 325-338.
Read now
Read now
Marta Rodríguez-Arias, María A Aguilar & José Miñarro. (2015) Therapies in early development for the treatment of opiate addiction. Expert Opinion on Investigational Drugs 24:11, pages 1459-1472.
Read now
Read now
Anselm Wong, Dawson Macleod, Jeff Robinson, Zeff Koutsogiannis, Andis Graudins & Shaun L. Greene. (2015) Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Clinical Toxicology 53:8, pages 815-818.
Read now
Read now
Articles from other publishers (26)
Suzanne Turner, Victoria M. Allen, Glenda Carson, Lisa Graves, Robert Tanguay, Courtney R. Green & Jocelynn L. Cook. (2023) Directive clinique no 443b : Opioïdes aux différentes étapes de la vie des femmes : Grossesse et allaitement. Journal of Obstetrics and Gynaecology Canada 45:11, pages 102146.
Crossref
Crossref
Suzanne Turner, Victoria M. Allen, Lisa Graves, Robert Tanguay, Courtney R. Green & Jocelynn L. Cook. (2023) Directive clinique no 443a : Opioïdes aux différentes étapes de la vie des femmes : Fertilité, contraception, douleur chronique et ménopause. Journal of Obstetrics and Gynaecology Canada 45:11, pages 102145.
Crossref
Crossref
Suzanne Turner, Victoria M. Allen, Glenda Carson, Lisa Graves, Robert Tanguay, Courtney R. Green & Jocelynn L. Cook. (2023) Guideline No. 443b: Opioid Use Throughout Women’s Lifespan: Opioid Use in Pregnancy and Breastfeeding. Journal of Obstetrics and Gynaecology Canada 45:11, pages 102144.
Crossref
Crossref
Suzanne Turner, Victoria M. Allen, Lisa Graves, Robert Tanguay, Courtney R. Green & Jocelynn L. Cook. (2023) Guideline No. 443a: Opioid Use Throughout Women’s Lifespan: Fertility, Contraception, Chronic Pain, and Menopause. Journal of Obstetrics and Gynaecology Canada 45:11, pages 102143.
Crossref
Crossref
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif & Gerard J Marek. (2023) A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder. Journal of Psychopharmacology 37:2, pages 144-154.
Crossref
Crossref
Eun-Ji Kim, Eun-Jung Hwang, Yeong-Min Yoo & Kyung-Hoon Kim. (2022) Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it’s time to act now. The Korean Journal of Pain 35:4, pages 361-382.
Crossref
Crossref
Hesham Farouk Elarabi, Amanda J. Lee, Abdu Adem, Abuelgasim Elrasheed, John Marsden & Hamad Al Ghaferi. (2022) Lower buprenorphine elimination rate constant is associated with lower opioid use. Psychopharmacology 239:10, pages 3213-3221.
Crossref
Crossref
Francisca Bastos, Ana Catarina Pinto, António Nunes & Sérgio Simões. (2022) Oromucosal products – Market landscape and innovative technologies: A review. Journal of Controlled Release 348, pages 305-320.
Crossref
Crossref
Thao Tranová, Oliver Macho, Jan Loskot & Jitka Mužíková. (2022) Study of rheological and tableting properties of lubricated mixtures of co-processed dry binders for orally disintegrating tablets. European Journal of Pharmaceutical Sciences 168, pages 106035.
Crossref
Crossref
Susana Barbosa Méndez, Maura Matus-Ortega, Ricardo Hernández Miramontes & Alberto Salazar-Juárez. (2021) Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice. European Journal of Pharmacology 891, pages 173718.
Crossref
Crossref
Ivan Urits, Cynthia Pham, Daniel Swanson, Kevin Berardino, Prudhvi Bandi, Ariunzaya Amgalan, Rachel J. Kaye, Jai Won Jung, Alan D. Kaye, Antonella Paladini, Giustino Varrassi, Adam M. Kaye, Laxmaiah Manchikanti & Omar Viswanath. (2020) The utilization of buprenorphine in chronic pain. Best Practice & Research Clinical Anaesthesiology 34:3, pages 355-368.
Crossref
Crossref
Brent Boyett. (2019) The Individualized Treatment of Opioid Use Disorder. Journal of Managed Care & Specialty Pharmacy 25:6, pages 634-636.
Crossref
Crossref
Stephen Chin Beng Lim, Stephan Schug & Janakan Krishnarajah. (2019) The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine. Pain Medicine 20:1, pages 143-152.
Crossref
Crossref
Martin Jönsson, Gill Mundin & Michael Sumner. (2018) Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences 122, pages 125-133.
Crossref
Crossref
Young-A Heo & Lesley J. Scott. (2018) Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. CNS Drugs 32:9, pages 875-882.
Crossref
Crossref
Mellar P. Davis, Gavril Pasternak & Bertrand Behm. (2018) Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 78:12, pages 1211-1228.
Crossref
Crossref
Rebecca McDonald, Øyvind Danielsson Glende, Ola Dale & John Strang. (2018) International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. Drug and Alcohol Review 37:2, pages 205-215.
Crossref
Crossref
Ryan Graddy & Darius A. Rastegar. (2017) Impact of a Mandated Change in Buprenorphine Formulation. Journal of Addiction Medicine 11:6, pages 435-439.
Crossref
Crossref
Kent Hoffman, Marvin L. Peyton & Michael Sumner. (2017) Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study. Journal of Addiction Medicine 11:3, pages 217-223.
Crossref
Crossref
Neha V. Maharao, Anand A. Joshi & Phillip M. Gerk. (2017)
Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements:
in vitro
proof of concept
. Biopharmaceutics & Drug Disposition 38:2, pages 139-154.
Crossref
Crossref
Richard J. Bodnar. (2017) Endogenous Opiates and Behavior: 2015. Peptides 88, pages 126-188.
Crossref
Crossref
John Strang, Kylie Reed, Karolina Bogdanowicz, James Bell, Rob van der Waal, Jenny Keen, Pete Beavan, Shelagh Baillie & Alastair Knight. (2017) Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study. European Addiction Research 23:2, pages 61-70.
Crossref
Crossref
Yi Wang, Alessandra Cipriano, Catherine Munera & Stephen C. Harris. (2016) Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. The Journal of Clinical Pharmacology 56:10, pages 1263-1271.
Crossref
Crossref
Erik W. Gunderson & Michael Sumner. (2016) Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film. Journal of Addiction Medicine 10:2, pages 124-130.
Crossref
Crossref
Michael W. Jann. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
351
372
.
Erik W. Gunderson, Peter Hjelmstr?m & Michael Sumner. (2015) Effects of a Higher-bioavailability Buprenorphine/Naloxone Sublingual Tablet Versus Buprenorphine/Naloxone Film for the Treatment of Opioid Dependence During Induction and Stabilization: A Multicenter, Randomized Trial. Clinical Therapeutics 37:10, pages 2244-2255.
Crossref
Crossref